DOI: 10.53469/jcmp.2025.07(04).40

Exploration on the Effects of the IL-6/Jak2/Stat3 Signaling Pathway on Myocardial Fibrosis and Heart Failure

Junyi Li[1], Yuanlin Lei[2,*]

[1]Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China
[2]Xi'an Hospital of Traditional Chinese Medicine affiliated to Shaanxi University of Chinese Medicine, Xi'an 710021, Shaanxi, China
**Correspondence Author*

Abstract: ***The IL-6/Jak2/Stat3 signaling pathway plays a crucial role in the pathogenesis and progression of myocardial fibrosis and heart failure. Its aberrant activation exacerbates inflammatory responses, cellular apoptosis, and fibrotic processes, ultimately impairing cardiac function. As a pro-inflammatory cytokine, IL-6 regulates cardiomyocyte survival, energy metabolism, and extracellular matrix remodeling via the Jak2/Stat3 pathway. In recent years, this signaling pathway has garnered significant research interest. Early studies have indicated that elevated IL-6 levels and excessive Stat3 activation are common in heart failure patients, while inhibition of Jak2 or Stat3 can attenuate fibrosis and improve cardiac function. Currently, targeted therapeutic strategies focusing on this pathway remain in an exploratory phase, with some interventions advancing to clinical trials. Future research should emphasize the cross-regulatory mechanisms of this signaling cascade and integrate artificial intelligence and big data analytics to develop personalized treatment strategies that enhance therapeutic efficacy while minimizing adverse effects. As investigations progress, targeted therapies directed at this pathway are expected to become a pivotal approach in the management of myocardial fibrosis and heart failure.***

Keywords: IL-6/Jak2/Stat3 signaling pathway, Myocardial fibrosis, Heart failure, Inflammation regulation, Targeted therapy.

1. Introduction

Myocardial fibrosis and heart failure are closely interconnected pathological conditions with a high global prevalence, particularly among elderly populations and individuals with chronic diseases [1]. Myocardial fibrosis is characterized by pathological alterations involving excessive collagen deposition and extracellular matrix remodeling, leading to myocardial stiffness, impaired systolic and diastolic function, and potential arrhythmogenesis. Heart failure, on the other hand, refers to the inability of the heart to effectively pump blood to meet physiological demands, typically manifesting as reduced cardiac output, pulmonary congestion, and peripheral edema [2]. These two conditions form a vicious cycle: myocardial fibrosis serves as a fundamental pathological substrate for heart failure by compromising ventricular compliance and contractility, while prolonged heart failure further exacerbates chronic inflammation and hemodynamic abnormalities, thereby accelerating fibrotic progression [3].

The IL-6/Jak2/Stat3 signaling pathway plays a pivotal role in the pathogenesis of cardiovascular diseases by influencing immune regulation, inflammatory responses, and cellular proliferation [4]. As a pro-inflammatory cytokine, IL-6 signaling depends on the activation of the Janus kinase 2 (Jak2) tyrosine kinase, which subsequently induces phosphorylation and nuclear translocation of the signal transducer and activator of transcription 3 (Stat3). This pathway orchestrates the inflammatory response, oxidative stress, and cardiomyocyte survival in the cardiovascular system; however, its aberrant activation exacerbates myocardial fibrosis and heart failure [5]. Studies have demonstrated a positive correlation between elevated IL-6 levels and the severity of myocardial fibrosis, while excessive activation of Stat3 promotes fibroblast proliferation, collagen deposition, and ventricular remodeling. Persistent Jak2 activation amplifies inflammatory and fibrotic processes while concurrently influencing apoptosis and autophagy in cardiomyocytes, further exacerbating cardiac dysfunction [6].

In recent years, research on the role of this pathway in myocardial fibrosis and heart failure has intensified. Both animal experiments and clinical studies have confirmed that heart failure patients exhibit significantly elevated IL-6 levels alongside abnormal Stat3 activation [7]. This signaling cascade plays a critical role in myocardial fibrosis progression, and the application of Jak2 or Stat3 inhibitors has been shown to mitigate fibrosis and enhance cardiac function. Currently, targeted therapeutic strategies directed at the IL-6/Jak2/Stat3 pathway, including IL-6 antagonists, Jak2 inhibitors, and Stat3-specific interfering molecules, are under active investigation, with some treatments advancing to clinical trials and demonstrating promising efficacy. Further exploration of this pathway not only deepens our understanding of myocardial fibrosis and heart failure pathophysiology but also holds potential for breakthroughs in precision medicine, ultimately offering more tailored intervention strategies for cardiovascular disease patients.

2. Biological Function of the IL-6/Jak2/Stat3 Signaling Pathway

2.1 Physiological and Pathological Roles of IL-6

IL-6 is primarily secreted by monocytes, macrophages, fibroblasts, and endothelial cells, exerting its effects through either classical signal transduction or transmembrane signaling mechanisms. It plays a pivotal role in acute inflammatory responses and immune regulation by facilitating B-cell maturation, enhancing T-cell differentiation, and stimulating hepatic synthesis of acute-phase proteins [8].

However, in pathological conditions, aberrantly elevated IL-6 levels contribute to chronic inflammation, tissue damage, and the onset of various diseases, including autoimmune disorders, malignancies, cardiovascular diseases, and metabolic syndromes [9].

The pathological effects of IL-6 encompass pro-inflammatory activity, abnormal cellular proliferation, and fibrotic progression. For instance, in autoimmune diseases such as rheumatoid arthritis, IL-6 modulates T-cell activation, promoting the expression of pro-inflammatory cytokines and sustaining localized inflammatory responses. Within the tumor microenvironment, IL-6 facilitates tumor cell proliferation, angiogenesis, and immune evasion. Moreover, in cardiovascular diseases, elevated IL-6 levels are strongly associated with myocardial fibrosis, atherosclerosis, and heart failure, with excessive activation of this pathway contributing to vascular remodeling and tissue injury.

2.2 Jak2/Stat3 Cascade Signaling Mechanism

IL-6-mediated signaling depends on its interaction with IL-6 receptor (IL-6R), which subsequently triggers the activation of the Janus kinase family member Jak2. Jak2 undergoes autophosphorylation, leading to downstream phosphorylation and nuclear translocation of the signal transducer and activator of transcription 3. This cascade governs multiple cellular functions, including proliferation, differentiation, metabolism, and inflammatory regulation [10].

Jak2 activation occurs via receptor complex formation, wherein IL-6 binding to membrane receptor gp130 induces Jak2 autophosphorylation, subsequently activating Stat3. Phosphorylated Stat3 functions as a dimer, translocates into the nucleus, and binds to specific DNA sequences, thereby regulating a repertoire of target genes, including pro-inflammatory mediators (TNF-α, IL-1β), anti-apoptotic proteins (Bcl-2, Mcl-1), and cell cycle regulators (Cyclin D1) [11]. Beyond IL-6, Jak2 activation is modulated by erythropoietin (EPO), growth hormone (GH), and other cytokines, underscoring its broad involvement in various biological processes.

Under pathological conditions, aberrant activation of the Jak2/Stat3 pathway is implicated in oncogenesis, cardiovascular diseases, and immune disorders [12]. In malignancies, excessive phosphorylation of Stat3 fosters tumor cell proliferation, inhibits apoptosis, and promotes angiogenesis, thereby conferring a survival advantage to neoplastic cells. Similarly, in chronic inflammatory diseases, sustained Jak2 activation exacerbates tissue damage and fibrosis, leading to progressive organ dysfunction.

2.3 Role of IL-6/Jak2/Stat3 in Apoptosis, Inflammation, and Tissue Repair

The IL-6/Jak2/Stat3 signaling pathway plays a crucial role in apoptosis, inflammation, and tissue repair. This pathway exhibits dual functionality—it can promote cell survival while also contributing to pathological damage.

2.3.1 Regulation of Apoptosis

The IL-6/Jak2/Stat3 signaling cascade regulates apoptosis by modulating the expression of anti-apoptotic genes such as Bcl-2 and Mcl-1, thereby inhibiting cell death and influencing tumor progression and chronic inflammatory conditions. In the context of myocardial injury, IL-6 activation via Stat3 signaling has been observed to reduce cardiomyocyte apoptosis and enhance survival rates [13]. However, in specific pathological environments such as the tumor microenvironment, excessive activation of this pathway may lead to continuous proliferation, allowing malignant cells to evade apoptosis and thereby accelerating disease progression.

2.3.2 Regulation of Inflammation

IL-6 serves as a pivotal pro-inflammatory cytokine, modulating immune cell activity through the Jak2/Stat3 signaling pathway. During infectious processes, this pathway enhances acute-phase protein synthesis, bolstering the body's defense mechanisms. However, in chronic inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease, and cardiovascular disease, persistent activation of this signaling pathway may result in sustained tissue damage and inflammatory progression. For instance, in atherosclerosis, IL-6 upregulates endothelial adhesion molecules, facilitating immune cell migration into the lesion site and thereby exacerbating inflammation [14].

2.3.3 Tissue Repair and Fibrosis

The IL-6/Jak2/Stat3 pathway plays a crucial role in tissue repair by regulating fibroblast activity and collagen synthesis. However, excessive activation of this pathway drives pathological fibrosis in conditions such as myocardial fibrosis, liver cirrhosis, and pulmonary fibrosis, leading to tissue stiffness and impaired organ function. In heart failure, persistently elevated IL-6 levels enhance fibroblast proliferation and extracellular matrix deposition, accelerating ventricular remodeling and further deteriorating cardiac function [13].

3. Role of IL-6/Jak2/Stat3 in Myocardial Fibrosis and Heart Failure

3.1 Role of IL-6/Jak2/Stat3 in Myocardial Fibrosis

3.1.1 IL-6-Mediated Inflammatory Response and Myocardial Fibrosis Development

IL-6 plays a critical role in cardiac injury and fibrotic progression. Studies have shown that NOTCH1 inhibition significantly reduces IL-6 expression, thereby attenuating cardiac inflammation. Following myocardial injury, IL-6 levels markedly increase, leading to immune cell infiltration and activation of macrophages and neutrophils, which secrete pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β). This inflammatory cascade exacerbates myocardial fibrosis, promotes cardiac remodeling, and ultimately impairs cardiac function.

Research indicates that NOTCH1 signaling inhibition effectively decreases IL-6 levels, thereby alleviating inflammatory responses and myocardial fibrosis. This

mechanism may be associated with NOTCH1's regulatory influence on cardiomyocytes and fibroblasts, particularly in controlling inflammatory cytokine production. Additionally, IL-6 activates the Stat3 signaling cascade, further stimulating fibroblast proliferation and collagen deposition, resulting in increased myocardial stiffness and impaired contractile function [13]. Targeting the IL-6 signaling pathway may therefore represent a potential therapeutic strategy for managing myocardial fibrosis and improving cardiac function.

3.1.2 Impact of Stat3 on Cardiac Fibroblast Activation

Signal transducer and activator of transcription 3 (Stat3) serves as a downstream mediator of cytokine receptor signaling and plays a key role in fibroblast activation. Fibroblast activation is a hallmark pathological process in myocardial fibrosis, characterized by enhanced fibroblast proliferation, elevated collagen secretion, and extracellular matrix remodeling.

Studies have demonstrated that IL-6-induced Stat3 activation enhances fibroblast activity, leading to accelerated fibroblast proliferation and increased synthesis of type I and type III collagen following myocardial injury [15]. Moreover, Stat3 plays an integral role in inflammatory regulation during fibrosis progression. In chronic inflammatory conditions, Stat3 amplifies inflammatory signals by activating macrophages and neutrophils, thereby reinforcing fibrotic responses. Additionally, sustained Stat3 activation may induce cardiomyocyte apoptosis, reducing the regenerative potential of myocardial tissue and further exacerbating cardiac dysfunction. Consequently, inhibiting Stat3 activity may mitigate fibroblast proliferation and excessive collagen deposition, contributing to the attenuation of myocardial fibrosis.

3.1.3 Jak2 Signaling and Collagen Deposition

Janus kinase 2 serves as a critical mediator of IL-6 signal transduction, promoting Stat3 phosphorylation and regulating cellular functions. Jak2's primary role in myocardial fibrosis is to enhance collagen deposition, a process driven by fibroblast activation and extracellular matrix remodeling.

Studies have revealed that Jak2 activation induces the expression of pro-fibrotic genes, including COL1A1 and COL3A1 (collagen proteins), matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs). COL1A1 and COL3A1 encode the principal collagen components implicated in myocardial fibrosis, whereas MMPs and TIMPs contribute to extracellular matrix degradation and remodeling. Excessive Jak2 activation increases collagen synthesis, leading to heightened myocardial stiffness and impaired ventricular compliance and contractility [16]. Furthermore, studies suggest that Jak2 may regulate fibrosis progression via the TGF-β signaling pathway, thereby accelerating the advancement of myocardial fibrosis. Consequently, Jak2 inhibition may offer a promising therapeutic strategy for mitigating fibrosis by reducing collagen deposition and improving cardiac function [16].

3.2 Association Between IL-6/Jak2/Stat3 and Heart Failure

The IL-6/Jak2/Stat3 signaling pathway plays a crucial role in the pathogenesis and progression of heart failure. As a pro-inflammatory cytokine, IL-6 influences physiological and pathological processes in cardiomyocytes via the Jak2/Stat3 pathway. Activation of this cascade can lead to myocardial fibrosis, exacerbated inflammatory responses, and deteriorated cardiac function.

3.2.1 Role of IL-6 in the Pathophysiology of Chronic Heart Failure

IL-6 levels are typically elevated in chronic heart failure and correlate with the severity of the disease. IL-6 promotes immune cell infiltration, induces myocardial fibrosis, and affects cardiac energy metabolism, thereby accelerating heart failure progression. Additionally, IL-6 may regulate cardiomyocyte apoptosis and autophagy, further aggravating cardiac dysfunction.

3.2.2 Stat3-Mediated Cardiac Remodeling and Contractile Dysfunction

Stat3 serves as a key transcription factor in the IL-6 signaling pathway and plays an essential role in cardiac remodeling. Studies have indicated that Stat3 activation influences cardiomyocyte viability, hypertrophy, and extracellular matrix alterations. Furthermore, Stat3 may regulate mitochondrial function and energy metabolism, affecting cardiac contractile capacity [17].

3.2.3 Clinical Significance of IL-6 Levels in Heart Failure Patients

Elevated IL-6 levels are strongly associated with the severity and prognosis of heart failure. Clinical studies have demonstrated that IL-6 can serve as a biomarker for disease progression and therapeutic efficacy assessment. Additionally, interventions targeting the IL-6 signaling pathway may represent novel therapeutic strategies for future heart failure treatment. These findings highlight the critical role of the IL-6/Jak2/Stat3 pathway in heart failure and underscore the need for further exploration of regulatory mechanisms to facilitate effective therapeutic development.

4. Advances in IL-6/Jak2/Stat3 Pathway Inhibitors for the Treatment of Myocardial Fibrosis and Heart Failure

4.1 Development of IL-6/Jak2/Stat3 Inhibitors

The IL-6/Jak2/Stat3 signaling pathway plays a central role in myocardial fibrosis and heart failure, particularly in chronic inflammation, extracellular matrix remodeling, and cardiomyocyte survival regulation. In recent years, significant advancements have been made in the development of inhibitors targeting this pathway. Several small-molecule inhibitors have entered clinical trial phases, aiming to block abnormal activation, slow fibrotic progression, and improve cardiac function [18].

Studies indicate that IL-6 activation via the Jak2/Stat3

pathway promotes fibroblast proliferation, collagen deposition, and cardiac remodeling, accelerating myocardial fibrosis and heart failure development [19]. Consequently, Jak2- and Stat3-specific inhibitors are considered potential therapeutic strategies for alleviating fibrosis progression and enhancing heart failure management. Currently, Jak2 inhibitors Ruxolitinib and Fedratinib have been validated in experimental models of myocardial fibrosis, demonstrating their ability to reduce collagen deposition and improve ventricular compliance [20]. Additionally, Stat3 inhibitors remain an active area of research, with certain candidates showing promise in reducing cardiomyocyte apoptosis and fibrosis-related gene expression.

4.2 Biologic Agents and Targeted Therapeutic Strategies

Biologic therapies have shown great promise in modulating IL-6 activity, reducing inflammation-driven fibrosis, and preventing heart failure progression. IL-6 monoclonal antibody Tocilizumab has been studied for its potential anti-inflammatory effects and myocardial remodeling benefits, with preliminary data suggesting fibrosis attenuation and improved left ventricular function [21].

Beyond IL-6 inhibition, Jak2 and Stat3 inhibitors continue to undergo optimization to enhance heart failure treatment efficacy and minimize adverse effects. Recent research proposes RNA interference-based approaches to suppress Stat3 expression, potentially reducing fibrosis-related gene activation in myocardial tissue [22]. Moreover, dual-target inhibitors, designed to simultaneously modulate Jak2 and Stat3, are currently in development, with the potential to reduce myocardial stiffening while preserving cardiac contractility.

4.3 Ongoing Clinical Trials and Future Prospects

Several clinical trials are currently assessing the efficacy of IL-6/Jak2/Stat3 inhibitors specifically in myocardial fibrosis and heart failure, providing important references for therapeutic potential. Tocilizumab, initially developed for autoimmune disorders, is being explored for cardiac applications, particularly in inflammation-driven fibrosis. Further research has demonstrated that Jak2 inhibitors such as Ruxolitinib exhibit anti-fibrotic properties in preclinical models, improving ventricular compliance and promoting myocardial repair [23].

Although Stat3 inhibitors remain in early clinical trial phases, preliminary studies suggest their potential to reduce fibrotic remodeling, lower cardiomyocyte apoptosis, and enhance overall cardiac function [23]. With advancements in biotechnology, targeted therapeutic strategies for myocardial fibrosis are expected to become more precise and effective. Nanomedicine-based drug delivery is being actively explored to optimize inhibitor specificity while minimizing side effects.

Additionally, combination therapies are gaining interest—IL-6 inhibitors are currently under evaluation alongside traditional heart failure treatments, aiming to maximize therapeutic efficacy and provide better disease management for fibrosis-associated cardiac dysfunction.

5. Conclusion

The IL-6/Jak2/Stat3 signaling pathway serves as a central regulator in myocardial fibrosis and heart failure progression, encompassing complex mechanisms involving inflammation, cell survival, energy metabolism, and extracellular matrix remodeling. Studies suggest cross-regulation between this pathway and NF-κB, mTOR, and Hippo signaling, influencing heart failure pathophysiology. Further investigation into interactions among these pathways will facilitate optimized therapeutic strategies.

Personalized medicine is emerging as a critical focus for future development. Given the variable genetic backgrounds and inflammatory profiles of different patients, the integration of biomarkers for IL-6 inhibitors or Jak2/Stat3 modulators will enhance precision in treatment selection.

The application of novel technologies, including single-cell sequencing, gene editing, and nanoparticle drug delivery, will deepen insights into this signaling pathway and promote targeted therapeutic strategies.

Multiple ongoing clinical trials evaluating IL-6/Jak2/Stat3 inhibitors have demonstrated initial efficacy, particularly in inflammatory disorders and oncology applications. Future research should prioritize investigations into cross-regulatory mechanisms, leveraging artificial intelligence and big data analytics to develop individualized treatment paradigms, thereby enhancing therapeutic effectiveness while minimizing adverse effects.

As research progresses, targeted interventions against this pathway are likely to shape the future landscape of heart failure management, providing more effective treatment options for patients.

References

[1] Netala VR, Hou T, Wang Y, Zhang Z, Teertam SK. Cardiovascular Biomarkers: Tools for Precision Diagnosis and Prognosis. Int J Mol Sci. 2025 Mar 30;26(7):3218.

[2] Shi M, Ning Z. In vivo and in vitro investigations of schisandrin B against angiotensin II induced ferroptosis and atrial fibrosis by regulation of the SIRT1 pathway. Sci Rep. 2025 Feb 20;15(1):6200.

[3] Zhang H, Dong W, Zhang L, et al. NOTCH1 promotes the elevation of GM-CSF and IL-6 through the EZH2/STAT3 pathway to facilitate the fibrotic state of the myocardium in DLBCL. PLoS One. 2025 Feb 14;20(2):e0316923.

[4] Liu Y, Sun X, Yuan M, et al. Enhanced lipid metabolism reprogramming in CHF rats through IL-6-mediated cardiac glial cell modulation by digilanid C and electroacupuncture stimulation combination. Front Cell Dev Biol. 2024 Sep 3;12:1424395.

[5] Chen W, Liu L, Tang M, et al. Type I collagen-targeted liposome delivery of Serca2a modulates myocardium calcium homeostasis and reduces cardiac fibrosis induced by myocardial infarction. Mater Today Bio. 2024 Jul 27;28:101162.

[6] Li H, Bian Y. Fibroblast-derived interleukin-6 exacerbates adverse cardiac remodeling after myocardial infarction. Korean J Physiol Pharmacol. 2024 May 1;28(3):285-294.
[7] Liu B, Wei Y, He J,, et al. Human umbilical cord-derived mesenchymal stromal cells improve myocardial fibrosis and restore miRNA-133a expression in diabetic cardiomyopathy. Stem Cell Res Ther. 2024 Apr 24;15(1):120.
[8] Zhu N, Li T, Bai Y, Sun J, Guo J, Yuan H, Shan Z. Targeting myocardial inflammation: investigating the therapeutic potential of atrial natriuretic peptide in atrial fibrosis. Mol Biol Rep. 2024 Apr 15;51(1):506.
[9] Wei J, Wang DF, Cui CC, et al. CXCL4/CXCR3 axis regulates cardiac fibrosis by activating TGF-β1/Smad2/3 signaling in mouse viral myocarditis. Immun Inflamm Dis. 2024 Apr;12(4):e1237.
[10] Zhang H, Dhalla NS. The Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease. Int J Mol Sci. 2024 Jan 16;25(2):1082.
[11] Wang M, Pan W, Wei C, et al. The Anti-Inflammatory Mediator 17(R)-Resolvin D1 Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis. Drug Des Devel Ther. 2023 Oct 11;17:3073-3083.
[12] Umbarkar P, Ejantkar S, Ruiz Ramirez SY, et al. Cardiac fibroblast GSK-3α aggravates ischemic cardiac injury by promoting fibrosis, inflammation, and impairing angiogenesis. Basic Res Cardiol. 2023 Sep 1;118(1):35.
[13] Li J, Wang M, Yao L, et al. Yixin Granules Reduce Myocardial Inflammation and Fibrosis in Rats with Heart Failure by Inhibiting the Expression of ADAMTS8. Int Heart J. 2023;64(4):741-749.
[14] Banik A, Datta Chaudhuri R, Vashishtha S, et al. Deoxyelephantopin-a novel PPARγ agonist regresses pressure overload-induced cardiac fibrosis via IL-6/STAT-3 pathway in crosstalk with PKCδ. Eur J Pharmacol. 2023 Aug 15;953:175841.
[15] Sano M. Complexity of Inflammation in the Trajectory of Vascular Disease: Interleukin 6 and Beyond. Ann Vasc Dis. 2023 Mar 25;16(1):8-16.
[16] Wang YL, Ma XX, Li RG, et al. T-Cell Mineralocorticoid Receptor Deficiency Attenuates Pathologic Ventricular Remodelling After Myocardial Infarction. Can J Cardiol.2023 May;39(5):593-604.
[17] Bai J, Wu B, Zhao S, et al. The Effect of PD-1 Inhibitor Combined with Irradiation on HMGB1-Associated Inflammatory Cytokines and Myocardial Injury. J Inflamm Res. 2022 Nov 18;15:6357-6371.
[18] Kariki O, Vlachos K, Dragasis S, et al. Atrial cardiomyopathy: Diagnosis, clinical implications and unresolved issues in anticoagulation therapy. J Electrocardiol. 2023 Jan-Feb;76:1-10.
[19] Jiang YL, Niu S, Lin Z, et al. Injectable hydrogel with dual-sensitive behavior for targeted delivery of oncostatin M to improve cardiac restoration after myocardial infarction. J Mater Chem B. 2022 Aug 31;10(34):6514-6531.
[20] Wang J, Wang M, Lu X, et al. IL-6 inhibitors effectively reverse post-infarction cardiac injury and ischemic myocardial remodeling via the TGF-β1/Smad3 signaling pathway. Exp Ther Med. 2022 Jul 18;24(3):576.
[21] Li HR, Zheng XM, Liu Y, et al. L-Carnitine Alleviates the Myocardial Infarction and Left Ventricular Remodeling through Bax/Bcl-2 Signal Pathway. Cardiovasc Ther. 2022 May 23;2022:9615674.
[22] Li F, Li SS, Chen H, et al. miR-320 accelerates chronic heart failure with cardiac fibrosis through activation of the IL6/STAT3 axis. Aging (Albany NY). 2021 Sep 28;13(18):22516-22527.
[23] Chen X, Liang J, Bin W, et al. Anti-hyperlipidemic, Anti-inflammatory, and Ameliorative Effects of DRP1 Inhibition in Rats with Experimentally Induced Myocardial Infarction. Cardiovasc Toxicol. 2021, Dec;21(12):1000-1011.